Recent Updates
Recently added Catalysts
TNGX Neutral Sentiment

Tango Therapeutics to Report Third Quarter 2025 Financial Results on Tuesday, November 4, 2025

Wednesday, October 29, 2025 BiopharmaWatch Research 1 min read
Add on Google
Key Takeaway: Tango Therapeutics, Inc. has announced that it will release its financial results for the third quarter of 2025 on November 4, 2025, at 9:00 AM ET. The results will be provided before the U.S. financial markets open. Notably, the company has chosen not to hold a conference call following the report. Tango Therapeutics is focused on developing therapies for cancer by utilizing the concept of synthetic lethality.
Price reaction · baseline $7.79 (2025-10-28 close) · hit after-hours · clean, no other TNGX news in the window
day 0 close · peak
+0.5%

Market Sentiment Analysis

BiopharmaWatch Analysis

From our catalyst data and publicly available data · not financial advice
Best trade, last catalyst
+24%
120-day peak, hindsight
Typical move
1%
average across 2 past catalysts
Cash runway
~78 mo
Minimal dilution risk
Lead asset
Perindopril-indapamide
Phase 3 · Diabetes Mellitus, Type 2

Full Press Release Details

BOSTON, Oct. 29, 2025 (GLOBE NEWSWIRE) -- Tango Therapeutics, Inc. (NASDAQ: TNGX), today announced that it will report third quarter 2025 financial results on November 4, 2025 at 9:00am ET, before the open of the U.S. financial markets. The company does not intend to hold a conference call.
About Tango Therapeutics
Tango Therapeutics is a clinical-stage biotechnology company dedicated to discovering novel drug targets and delivering the next generation of precision medicine for the treatment of cancer. Using an approach that starts and ends with patients, Tango leverages the genetic principle of synthetic lethality to discover and develop therapies that take aim at critical targets in cancer. For more information, please visit www.tangotx.com.
Investors and Media:

Frequently Asked Questions

When will Tango Therapeutics report Q3 2025 results?

Tango Therapeutics will report its Q3 2025 financial results on November 4, 2025.

What time will the Q3 results be reported?

The Q3 results will be reported at 9:00 AM ET.

Will there be a conference call after the Q3 report?

No, Tango Therapeutics does not plan to hold a conference call.

What is the focus of Tango Therapeutics?

Tango Therapeutics focuses on developing precision medicine for cancer treatment.

What principle does Tango Therapeutics employ in its research?

The company uses the genetic principle of synthetic lethality in its drug development.

ShareAdd on Google
Tags: TNGX Viatris Investor Conferences Healthcare Tango Therapeutics financial results biotechnology precision medicine
Last updated: Oct 29, 2025

Biotech snapshot

Cash runway
$1014M liquidity · $13M/mo burn
~78 mo
Minimal dilution risk
Lead asset
Perindopril-indapamidePhase 3
Diabetes Mellitus, Type 2 →

Catalyst track record

+24%
best trade around TNGX's most recent catalyst

Peak hindsight return over a 120-day window, across 2 tracked FDA/PDUFA catalysts for TNGX.

See every catalyst's timing & PoA →